News — Oxford Cancer

Research team receives $25m Cancer Grand Challenges award

7 March 2024

A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle the solid tumours in children challenge.

Professor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre

17 October 2023

Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.

Rad cam library and a woman at a machine in a lab

How Oxford has shaped cancer science

4 February 2022

As part of World Cancer Day 2022 we are diving into 10 of Oxford’s most impactful historical and modern contributions to the field of cancer science and treatment. Read more about what Oxford researchers have done to shape this ever-important area of medical science.

An image of the fungus Cordyceps sinensis. Cordycepin is derived from Cordyceps sinensis, which has been used in traditional Chinese medicine for hundreds of years to treat cancers and other inflammatory diseases. Thanks to this Oxford University-NuCana partnership, a new drug called NUC-7738 has been derived from Cordycepin and is now being tested in clinical trials.

Anti-cancer drug derived from fungus shows promise in clinical trials

6 October 2021

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Vaccine for treating cancer made possible using Oxford COVID vaccine technology

3 September 2021

A new publication from Benoit Van den Eynde's group has shown that a viral vector cancer vaccine generates effective anti-tumour immune responses and, in combination with immunotherapy, decreases tumour size and increases survival rates in mouse models.

First patient dosed with drug designed to re-sensitise patients to cancer treatment

5 August 2021

The first patient has been dosed using new drug PORT-2 in Oxford, which hopes to improve treatment options for melanoma and Non-Small Cell Lung Cancer (NSCLC) and resensitise patients with checkpoint therapy-resistant tumours

Adrian Hill elected to Royal Society

11 May 2021

Six scientists from the University of Oxford have joined the Royal Society as Fellows, including vaccine and cancer researcher Prof. Adrian Hill

Prof Andi Roy receives new award for immune-cell research

18 March 2021

Co-funded by Cancer Research UK and Children with Cancer UK, Andi is one of 5 to receive £1 million each to investigate children’s and young people’s cancers.

New Oxford spin-out Singula Bio launches

3 February 2021

Singula Bio, co-founded by Professors Ahmed Ahmed, Enzo Cerundolo and Enda McVeigh from the Nuffield Department of Women’s & Reproductive Health, aims to become a world leader in developing neoantigen-based individualised cell therapies to use against difficult-to-treat solid malignancies such as ovarian cancer.

Oxford spin out financed $6.8m for research into oncolytic therapies

7 January 2021

Oxford spin out company Theolytics has closed a $6.8m deal to support their work into developing novel cancer therapies from viruses

Susan Cakebread in a hospital bed with cancer research nurse, having her blood taken during a routine check up

Being a part of cancer drug discoveries

17 December 2020

Susan Cakebread, gives her account of being on the Tebentafusp experimental immunotherapy drug trial in 2014. A Phase 1 trial for melanoma that began here in Oxford, and is now entering Phase 3 trials after giving Susan back her life.

Person holding a test tube with a new drug inside

New melanoma drug a step closer to the clinic

24 November 2020

Clinical trials into the use of Tebentafusp for metastatic uveal melanoma have been conducted by the University of Oxford and Immunocore. The positive results of the most recent trial mean this drug could now be used in future treatment.

What we can learn from cancer survivors

19 November 2020

Understanding how an individual survives cancer, and why they respond well to therapy, can be vital in identifying new therapeutic targets. A new project seeks to see why some advanced pancreatic cancer patients overcome the odds and respond positively to treatment.

Search results (16)